Von Willebrand Factor — A New Target for TTP Treatment?
摘要
Thrombotic thrombocytopenic purpura (TTP), a rare thrombotic microangiopathy, is defined by a mechanical hemolytic anemia, severe thrombocytopenia, and visceral ischemia due to systemic platelet-rich microthrombi. Specifically in TTP microthrombi, von Willebrand factor, not fibrinogen, is the protein that binds to platelets.1 Von Willebrand factor is a multimeric glycoprotein that is crucial for physiologic platelet adhesion and aggregation at high shear rates of blood flow, and the largest von Willebrand factor multimers are the most adhesive. The hemostatic power of von Willebrand factor is regulated by a specific cleaving metalloprotease named ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 repeats, . . .
引用本文（GB/T 7714）
Agnès Veyradier. Von Willebrand Factor — A New Target for TTP Treatment?[J]. New England Journal of Medicine, 2016.
引文网络
本站仅收录题录与摘要供学习参考，全文版权归属出版方；如有侵权请联系我们删除。